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The growing number of electronic intracardiac devices (pacemakers,  
resynchronizers and defibrillators) and non-electronic devices (percutaneous 
occluders) implanted, combined with certain common characteristics in the treated 
population (underlying heart disease, advanced age, kidney disease, multiple 
associated pathologies), have led to a change in the spectrum of presentation of 
endocarditis, with an increase in cases related to these devices. These infections 
pose diagnostic and therapeutic challenges due to the complexity of the patients, 
the microorganisms involved –who frequently generate the formation of biofilm- 
and the percutaneous or surgical techniques involved in the removal of material.  
All these circumstances require a multidisciplinary approach.
Keywords: endocarditis, cardiac implantable electronic device (CIED), infection, 
biofilm, prophylaxis
1. Introduction
Endocarditis is defined as the inflammation of the endothelium. The first case 
of endocarditis was described by Lazare Rivière in the seventeenth century. Since 
then, the clinical, etiological, epidemiological and therapeutic knowledge around it 
has expanded remarkably. Nevertheless, it is a complex disease in constant evolu-
tion that requires a multidisciplinary approach. Most endocarditis has an infectious 
cause of bacterial origin. Being a disease of the endocardium, it not only affects 
native structures -more frequently the valves or cardiac structures subjected to 
special hemodynamic conditions such as in congenital heart disease-, but also other 
endothelizable surfaces, such as valve prostheses, catheters, electrodes, or percuta-
neous devices.
In this chapter we will address endocarditis on Cardiac Implantable Electronic 
Devices (CIED).
2.  Endocarditis and cardiac implantable electronic devices (CIED) with 
leads
2.1 Epidemiology
Infective endocarditis is a serious disease, whose incidence, despite therapeutic 
advances, remains relatively stable (although data regarding countries with low 
health resources are scarce). In developed countries, its incidence is estimated 
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at 1 per 1000 hospital admissions and 1.5–9.6 cases per 100000 inhabitants [1, 2]. 
While in countries with limited resources it continues to be closely related to rheu-
matic valve disease, in developed countries it is fundamentally related to degenerative 
valve disease, valve prostheses and CIED. The use of implantable cardiac electronic 
devices (pacemakers [PM], implantable cardioverter-defibrillators [ICD], cardiac 
re-synchronized therapy [CRT]) has increased by 4.7% annually between 1993 and 
2009 with a growth of 96% in the entire period. The number of implanted pacemak-
ers increased by 55.6% (especially bicameral), while that of defibrillators did so by 
504% [3, 4]. Such increase is due to a number of factors: the aging of the population, 
the complexity of their pathologies, the new indications and the advance in implanta-
tion techniques. However, the growth of infections associated with these devices has 
raised disproportionately and is estimated at 210% between 1993 and 2008 [4, 5].
2.2 Classification of CIED infections
• Post-operative wound inflammation: occurs within 30 days of implanta-
tion, with wound inflammation or ‘stitch abscess’, in the absence of definite 
evidence of infection and not necessarily requiring antimicrobial therapy 
(possible skin reaction to dressings, sutures or antiseptics) [6].
• Uncomplicated generator infection: cellulitis confined to the generator site, 
including purulent discharge, abscess, fistula or device erosion in the absence 
of systemic involvement, and negative blood cultures.
• Complicated generator infection: generator infection plus involvement of any 




a. Symptoms/signs of systemic infection, NO signs of generator pocket 
infection AND echocardiography consistent with vegetation(s) attached to 
lead(s) AND presence of major Duke microbiological criteria.
b. Symptoms/signs of systemic infection, NO signs of generator pocket 
infection AND culture, histology or molecular evidence of infection on 
explanted lead.
 ○ Possible.
a. Symptoms/signs of systemic infection AND echocardiography consistent 
with vegetation(s) attached to lead(s), BUT NO major Duke microbiologi-
cal criteria present.
b. Symptoms/signs of systemic infection AND major Duke microbiological 
criteria present, BUT NO echocardiographic evidence of lead vegetations.
c. Pulmonary emboli are considered supportive evidence of lead infection in 
the absence of definite evidence of infection.
• CIED -associated native or prosthetic valve endocarditis.
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Duke criteria for definite endocarditis satisfied, with echocardiographic evidence 
of valve involvement in a patient with an CIED in situ.
The last two forms are considered by the European Society of Cardiology (ESC) 
as endocarditis related to CIEDs, and we will now focus on them, not forgetting that 
they coexist with local infection of the generator pocket in up to 10–50% of cases 
(although in some recent series, the figure is closer to 10%, which suggests that 
causative microorganism reached PM leads by haematogenic way in a high propor-
tion of case) [7].
Different epidemiological studies, with follow-up ranging from 6 weeks to 
11 years, estimate the incidence of CDI-related infection at 2% [6, 8], although the 
figures are highly variable depending on the criteria used (0–6% and up to 19% if 
intra-abdominal devices are included) [9]. Between 10 and 23% of these infections 
meet the criteria for endocarditis [2, 7, 10].
A study in 7424 patients who underwent a pacemaker and/or ICD device 
implantation demonstrated an increasing incidence of IE in pacemakers [7]. It 
represented almost 10% with an increment from 1.25 to 9.32% of all IE between the 
period 1987–1993 compared to the period 2008–2013. Another prospective cohort 
study, using data from the International Collaboration on Endocarditis–Prospective 
Cohort Study (ICE-PCS), conducted from June 2000 through August 2006 in 61 
centers in 28 countries, found that cardiac device infective endocarditis accounted 
for 6.4% of all cases of definite infective endocarditis [11].
2.3 Risk factors
Several studies have identified the following risk factors for the development of 
infection on CIED [2, 7, 8, 11–13]:
Factors associated with the patient: Several of them coexist in up to 50% of 
patients [7].




• Other comorbidities such as heart failure or (chronic obstructive pulmonary 
disease (COPD).
• Neoplasia.
• Use of corticosteroids.
• States of immunosuppression.
Factors associated with the procedure
• Non-first implant: Infection is more frequent in replacement or update 
procedures (1–4%) than in first implantation (0.5–0.8%) The risk of CIED 
infection is much greater after generator change or device revision. It has 
been suggested that this is related to bacterial contamination of the avascular 
pocket that is formed around the generator, which may impede penetration of 
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systemic antimicrobials and inflammatory cells during generator replacement. 
For this reason, some operators advocate the removal of the capsule in battery 
replacement.
• Shaving the skin with a blade (risk of disruption of the skin barrier).
• Poor preparation of the skin.
• Not using antibiotic prophylaxis.
• Fever in the previous 48 hours.
• Hematoma.
• Number of electrodes and complexity of the procedure.
• Duration of the procedure.
• Operator experience.
Factors related to other procedures and health care
• Previously carrying a transvenous transitory pacemaker.
• Invasive procedures related to health care (nosocomial and non-nosocomial) and 
or hospitalization, which may produce bacteremia leading to CIED infection, 
were identified in the previous 6 months in about 45–50% of the IE-ICED [7–11].
2.4 Physiopathology and etiology
According to estimates from the U.S Food and Drug Administration (FDA) and the 
European trade association representing the medical technology industries, (MedTech 
Europe), more than 500000 types of medical devices have currently entered the global 
market. Invasive medical devices, including indwelling and implantable devices, 
represent just a fraction of these [14, 15]. More than a million cardiovascular electronic 
devices are implanted worldwide each year [16]. Devices used in cardiovascular 
surgery and interventionism are inserted into the body tissues by breaching the skin 
or mucous membranes. No matter where the surgically invasive device is placed, it is 
a foreign body. Even a mild tissue response alters the local immune defenses, creating 
a “locus minoris resistentiae”, which is vulnerable to bacterial attack. Especially the 
devices in contact with the bloodstream, can potentially cause sepsis.
CIED infection, can have a local or a distant origin.
2.4.1 Local origin
Human skin is very resistant to infection. This resistance is due to physical 
(thickness, exfoliation), chemical (pH, secretions) and immunological (cellular 
and humoral) factors.
The resident flora is also an important factor. This flora is made up of bacteria 
that live attached to the skin and under normal circumstances, they do not cause 
infection and prevent the proliferation of other strains as well. When the skin 
barrier is broken, the entry of microorganisms from the adjacent skin is facilitated. 
Most infections from these devices are caused by coagulase negative staphylococci 
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(CoNS), which are the most common microorganisms in the normal flora of 
the upper part of the skin of the thorax (especially Staphylococcus epidermidis). 
Staphylococcus aureus is not part of this resident flora, but it can become a persistent 
colonizer of the nasal mucosa, pharynx, and skin, especially in kidney patients, 
diabetics, some skin diseases, and hospital workers.
Phases of infection
• Colonization of the CIED pocket by microorganisms from the surgical 
equipment (air or personnel) or more frequently from the patient’s own skin. 
Disinfection reduces the number of bacterial colonies, but in the presence of a 
foreign body, the inoculum to produce an infection is lower. The susceptibility 
of surgically invasive devices to bacterial colonization is due to reduced effec-
tiveness of human immune defenses at the implant–tissue interface [12]. The 
longer the procedure, the higher the rate of colonization of the surgical sites.
However, colonization is not synonymous with infection, since it must occur:
Adhesion and BIOFILM formation (Figure 1) [13, 14].
Biofilm formation occurs in five steps:
• Initial reversible anchoring of bacteria in “planktonic” or “free” form to surfaces 
by unspecific forces.
• Irreversible anchorage: Once anchored, a bacterial monolayer will begin to form 
and an extracellular protective matrix composed of extracellular polysaccha-
rides, extracellular proteins, cellular debris and nucleic acids will begin to be 
produced. Both, along with the collagen and fibrinogen deposited in damaged 
tissues and on biomaterials, favors the anchorage of bacteria with specific 
receptors. The formation of hematomas facilitates this process.
• Maturation: the development of a biofilm favors the growth of the colonies, 
with a complex three-dimensional framework and a great resistance to anti-
biotics. Sometimes different bacterial species can coexist in the same biofilm. 
There are complex genetic interactions between the bacteria in these biolayers 
known as “quorum sensing”.
Figure 1. 
BIOFILM formation.
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• Dispersion. In the last step, some cells of the mature biofilm begin to dissociate 
and disperse again through the environment as planktonic cells to start a new 
cycle and thus the infection is dispersed.
2.4.2 Remote origin
During the early post-implant period, damage to the vascular wall and the 
formation of hematomas can favor the settlement of germs from the bloodstream in 
the implant area; thus, it is very important to avoid the development of bacteremia 
by removing unnecessary intravascular and urinary catheters.
The infection can spread to the endovascular structures, during the healing and 
resorption phases of hematomas, from the pacemaker pocket.
Conversely, and generally later, endovascular elements (electrodes) can present 
fibrin and platelet deposits on erosions produced by friction, deterioration or 
turbulent flows, on which bacterial colonies can settle and proliferate in a process 
similar to that of endocarditis, which can also spread to the adjacent endocardium.
Concomitant valve involvement is estimated in about 37.2% of cases, most fre-
quently tricuspid valve [11], aortic or mitral valve vegetations are present in 10–15% 
of patients with CIED endocarditis and valve involvement in CIED infection is 
associated with higher in-hospital mortality.
As previously mentioned, between 40 and 50% of patients with CIED have a 
history of admission, manipulation or invasive procedure in the previous 6 months, 
potentially responsible for bacteremia. The risk is especially high when the bactere-
mia is due to Staphylococcus aureus (35–45%) [6].
In any case, given that many “presumed local” infections can progress to 
the intravascular components of the device and vice versa, the barrier between 
local and endovascular infection can be difficult to establish. Once the generator 
or proximal leads have eroded through the skin, a device should be considered 
infected, whatever the mechanism that caused the erosion.
2.5 Microbiology
Gram-positive bacteria are responsible for the vast majority of CIED infections 
(68–93%). Staphylococci, account for 60–80% of cases. Depending on the series, 
there is a predominance of infections caused by S Aureus or coagulase-negative 
staphylococcus (CoNS), although with few differences in their prevalence. Among 
the CoNS, Staphylococcus epidermidis and Staphylococcus Saprophyticus stand out. 
Methicillin resistance (MR) among Staphylococci varies among studies A high rate 
of MR in CoNS is associated with a healthcare environment source, reaching 50% in 
some series. For S aureus the rates of MR range between 2.6% (Germany) and 55% 
(USA). Gram-negative bacteria (GNB) are also identified in a percentage close to 
15%. The higher proportion of GNB may be due to the large rate of different comor-
bidities, which is associated to more frequent invasive diagnosis or treatment mea-
sures. Polymicrobial infection sometimes involves more than one species of CoNS, 
(2–24% according to series). In a percentage between 8 and 15%, it was not possible 
to cultivate the responsible germ. Cases related to fungi are anecdotal [5, 6, 17–19].
2.6 Diagnosis
The diagnosis of IE-CEID, as in valve prostheses, is inconclusive in up to 30% of 
cases, according to the Duke criteria [20]. For this reason, in the guidelines pub-
lished by the European Society of Cardiology in 2015, three additional criteria were 
proposed to increase sensitivity in diagnosis [19].
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In any case, the IE-CEID diagnosis is based on three points [19, 21].
2.6.1 Clinical presentation
The clinical manifestations of IE-CIED can be variable, since it can combine signs 
and symptoms of local infection, with symptoms and signs of systemic infection.
When there is involvement of the pacemaker pocket, diagnosis can be easier 
since there will be typical signs of inflammation, such as pain, redness and increased 
temperature in the implantation area. In addition, there may be an increase in size, 
either due to the presence of hematoma related to the implant (which should alert to 
an increased risk of infection) or fluctuation due to the formation of pus, adhesion 
of the skin as well as spontaneous and sometimes intermittent pus drainage due to 
dehiscence of the suture or fistulization of the skin (Figure 2).
Any exteriorized device should be considered infected (although initial exteri-
orization was related to aseptic necrosis of the skin due to tension of the device in a 
small pocket).
Once the pocket is infected, the electrodes are frequently affected in its subcuta-
neous and extravascular portion, and affect the intravascular portion as well. When 
there is involvement of the intravascular components, that is, endocarditis of the 
leads and vascular part of the system, signs and symptoms of systemic infection 
will appear, with fever, chills, asthenia and anorexia. These data can appear larvae 
and in the absence of associated involvement of the pacemaker pocket, they can be 
more difficult to interpret. In a low percentage of patients, signs and symptom of 
frank sepsis will appear. In case of associated valvular involvement, data of valvular 
dysfunction and heart failure may also appear.
Clinical manifestations related to septic lung embolism may also appear from 
vegetations of the PM leads or tricuspid valve.
Among laboratory results data, the acute phase reactants (C-reactive protein, 
increased sedimentation rate, leukocytosis and procalcitonin) increase. Although 
these alterations point us towards a systemic infection, acute phase reactants can 
also appear in local infections.
Regarding the chronology of infections, several aspects must be taken into account:
• In the first 30 days, skin or exudate or superficial erythema may appear in 
relation to infection of the suture or allergic reaction,
• Depending on the responsible germ, the temporary clinical course may 
vary. In the case of S Aureus infections, parturition is usually earlier and 
Figure 2. 
Exteriorized device.
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the progression to systemic disease faster than in the case of germs such as 
S Epidermidis or Propionibacterium acnes, in which it can be latent and even 
reactivate late with delayed handling.
2.6.2 Microbiological evidence
We have already discussed the main agents involved, now we will address how 
and when microbiological samples should be collected and processed. Appropriate 
microbiological samples include: culture of blood, lead fragments (ideally distal 
and proximal), lead vegetation (proximal and distal tips), generator pocket tissue 
and pus from a generator pocket wound.
Blood sample extraction [6, 21].
• Should be collected as soon as possible, and whenever possible before starting 
antibiotic treatment.
• Collection of multiple samples increases diagnostic sensitivity: three sets of 
aseptically collected, optimally filled blood cultures should be taken from 
peripheral sites with ≥6 h between them, especially in patients with non-acute 
presentation.
• To avoid an undesirable delay in patients with suspected IE-CIED and severe 
sepsis or septic shock at the time of presentation, two sets of optimally filled 
blood cultures should ideally be taken at different times within 1 h and prior to 
the start of empirical antimicrobial therapy.
• Follow -up blood cultures should be obtained 48 to 72 h after antimicrobial 
therapy is begun, and every 48–72 hours until clearance of bacteremia is 
documented.
• Blood cultures should be taken 48–72 h after removal of an infected  
CIED.
Regarding blood culture, the following considerations must be taken into 
account:
• In a variable percentage, around 10%, it will not be possible to grow any 
microorganism.
• The interpretation of a single positive culture for an organism, common 
contaminant of the skin flora, should not be interpreted systematically as 
bacteremia and should be evaluated within the overall clinical context.
• In case of bacteremia originated at a clear distant infectious focus (abdominal, 
urinary, respiratory) and due to germs that do not frequently cause endocardi-
tis on devices (enterobacteria, pneumococci), affectation of the device should 
not be assumed unless proven otherwise.
• All cultured samples must be processed in different culture media and in 
specific media for slow-growing organisms.
• When interpreting the results of the cultured electrodes, it should be consid-
ered their potential contamination when extracted through the explant area.
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• To the contrary, in the presence of remote bacteremia by S Aureus, the risk of 
device infection is very high (35–45%).
2.6.3 Imaging
Different imaging techniques are used for the diagnosis of IE – CIED and, 
therefore, we will speak of Multimodal imaging when referring to them [21, 22].
First line technique, due to its availability and safety, is echocardiography. 
Initially, an echocardiogram should be performed in all patients with CIED infection, 
either local or systemic. Transthoracic echocardiogram (TTE) will allow us to glob-
ally assess all the structures of the heart as well as their function (Figure 3). Despite 
the advantage of the proximity of the right cavities to the thoracic wall, the presence 
of metallic electrodes generates artifacts that make it difficult to assess associated 
vegetations. Occasionally, images compatible with vegetations can be identified, 
associated with the electrodes, the valves or the endocardium; although their absence 
does not exclude the diagnosis, since sensitivity is low.
Regardless of the result of the TTE, a Transesophageal echocardiography (TOE) 
should be performed in all patients with CIED infection suspected of systemic 
involvement, and probably in carriers of intracardiac devices in the presence of S 
Aureus bacteremia (Figure 4). Even though the sensitivity is higher than in ETT, 
it is still less than 100% in the case of devices. The reasons for the low sensitivity 
include: the small part visualized of the cava, the difficulty to assess electrodes in 
the coronary sinus, or the lesser proximity to the transducer. Three-dimensional 
(3D) echo, if available, can provide information about vegetation’s morphology and 
size (Figure 5). On the other hand, there are images that are difficult to interpret as 
they may correspond to fibrin strands or small thrombi adhering to the surface of 
the leads, more frequent in the right cavities due to a slower flow.
In some centers, intracardiac echo (ICE) is also used for the diagnosis of vegeta-
tions based on electrodes, with greater sensitivity for the detection of vegetations in 
the case of high suspicion without diagnostic images. As drawbacks, it is an invasive 
and expensive technique [23].
In the case of uncertain diagnosis and high suspicion of endocarditis in the 
absence of diagnostic criteria or doubts about the extent of a local infection, 
Figure 3. 
Lead vegetation TTE.
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Nuclear Medicine or hybrid technique can be used, based on the detection of 
metabolic or inflammatory activity.
Positron Emission Tomography-CT (PET-CT) is generally performed using 
a single acquisition (generally at 1 h) after administration of 18F-FDG, which is 
actively incorporated in vivo by activated leucocytes, monocytes, macrophages 
and CD4+ T-lymphocytes accumulating at the sites of infection. Its limitations 
are the low resolution for foci smaller than 5 mm, its price, the high radiation and 
the early post-implant or post-surgery period, since the isotope uptake can occur 
in any inflamed tissue or with metabolic activity, including thrombi and tumors. 
Sensibility of this test it is estimated around 87% and its specificity around 94% 
(Figures 6 and 7).
Scintigraphy (SPECT) with labeled leukocytes can be combined with CT. 
Compared to PET-CT, it has the disadvantages of a lower availability, a longer 
duration -since it requires 2 separate acquisitions (2 and 24 hours)- and the use 
of blood products. On the other hand, it is cheaper, has greater utility in the post-
implantation/postoperative period, exposes less radiation and a greater specificity 
is reported, close to 100% (except for non-pyogenic agents such as Candida or 




Lead vegetation 3D echo.
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Beyond imaging techniques focused on evaluating of vegetations and inflamma-
tory activity, a chest radiograph in 2 projections or even a CT should be performed 
to assess the type of device (sometimes unknown), the presence of breakage, 
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the pulmonary parenchyma as there may be images suggestive of septic embolism 
or infectious pulmonary involvement (Figure 8).
2.7 Prevention and prophylaxis
Before addressing the treatment of IE-CIED we will discuss how to prevent 
infectious complications.
2.7.1 General measures
Any implant procedure must be performed following the usual aseptic surgical 
standards. Additionally, it is recommended to adhere to the following guidelines:
• Carry out the procedure in an appropriate place, with adequate ventilation. 
The air requirements specified for cardiac catheterization laboratories (15 air 
changes/hour) are less than the 25 air changes/hour recommended for the 
operating room [6].
• Do not shave the skin with blades. When trimming hair, shave with a single-use 
electric head or with depilatory cream, before the procedure and outside the 
implant room [6, 30].
• Prepare the skin with an alcoholic solution of chlorhexidine (minimum 2%)  
or as an alternative for allergic individuals, use povidone iodine in alcohol  
[6, 18, 27–29].
• Avoid unnecessarily long procedures, best if performed by a first operator or 
an experienced supervisor [6, 11, 26, 30].
• Carry out a correct hemostasis to avoid the formation of hematoma. In 
the case of anticoagulated patients in whom anticoagulation should not 
be interrupted, do not use bridging therapy with heparin and look for an 
INR close to 2. Individualize treatment in the rest of antiplatelet or antico-
agulated patients. Local thrombin solutions can be considered to facilitate 
hemostasis [18, 26].
• Do not perform procedures in patients with suspected active infection or fever 
in the past 48 hours [6, 11, 18].
Figure 8. 
Pulmonary infectious involvement in IE-CIED. TC.
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• Consider the subpectoral implantation in malnourished or very thin  
patients [18, 26, 30].
2.7.2 Antibiotic prophylaxis
Antimicrobial prophylaxis should be administered on time to ensure, at the 
time of incision and throughout the procedure, that the tissue and plasma con-
centrations exceed the MIC for the microorganisms commonly associated with 
infection. This would normally be within 1 h for intravenous drugs given as a 
bolus or short infusion, but for some longer infusions that are given over 30 min-
utes or more, they may need to be started earlier to ensure that the infusion is 
completed at least 20 minutes before incision (e.g. vancomycin and fluoroquino-
lones) [6, 18, 19, 26–30].
Currently, the use of a dose of cefazolin (2 gr) or another first-generation cepha-
losporin or flucloxacillin (1–2 g) is recommended, one hour prior to the procedure. 
In patients allergic to Beta lactams or when the local incidence of MR Staphylococci 
is very high, vancomycin is recommended (vancomycin requires a mg/kg iv slower 
rate of infusion to prevent systemic vasodilatation and erythema within 2 hours 
before incision) or teicoplanin as an alternative regimen. If a glycopeptide is to 
be used, teicoplanin has some practical advantages over vancomycin in terms of 
administration as it can be given as a bolus (400 mg iv 5 minutes) rather than a 
long infusion. Teicoplanin resistance is more frequent than vancomycin resistance 
among Staphylococci (including CoNS), but both are uncommon. In case of allergy 
to both, assess linezolid/daptomycin.
In very prolonged procedures or in case of heavy bleeding, a second dose of 
intraprocedural antibiotic can be considered [12].
For elective procedures, S. aureus colonization can be detected by nasal swabs. 
Nasal treatment with mupirocin and chlorhexidine skin washing can reduce coloni-
zation and has been shown in some surgical studies to reduce the risk of infection, 
but there are no studies relating specifically to CIED interventions [6, 18, 30].
Antibiotic doses after wound closure are not recommended [6, 30]. The use of 
local antibiotic delivery is not recommended [6, 21, 30] as well.
Antimicrobial ‘envelopes’ have been developed to deliver antimicrobial agents 
locally into the generator pocket at the time of implantation or generator replace-
ment. A product that delivers rifampicin and minocycline locally was tested in a 
randomized, controlled clinical trial WRAP-IT to assess its safety and efficacy in a 
population of patients who were at increased risk for CIED pocket infection. The 
envelope was significantly more effective at preventing infection than standard 
protocols. There is no formal recommendation for the use of these covers but it 
could be considered in high-risk patients [29, 30].
Antimicrobial prophylaxis is not recommended for dental or other invasive 
procedures not directly related to device manipulation to prevent CIED infection, 
except in case of infected tissue manipulation [26].
2.8 IE-CIED treatment
Treatment is based on two pillars: the removal of the device and antimicrobial 
therapy.
2.8.1 The removal of the device
Complete removal of the device, electrodes, or abandoned remains, is indicated 
in patients with any CIED infection, with the exception of superficial infections 
Advanced Concepts in Endocarditis - 2021
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related to the incision and provided that they do not occur with exteriorization of 
the device or erosion of the skin [24, 30–32].
Explantation is indicated in case of:
• local pocket infections without data of systemic involvement (negative blood 
cultures).
• infections of the pocket with systemic involvement, without vegetations on the 
electrodes or valves.
• infections of the pocket with systemic involvement, with evidence of vegeta-
tions in electrodes and/or valves and/or embolisms.
The device should also be removed in CIED carriers in case of [21, 30]:
• bacteremia or fungaemia caused by S Aureus, CoNS, Cutibacterium spp. and 
Candida spp.
• bacteremia with Alpha- or Beta-Hemolytic Streptococcus spp. and 
Enterococcus spp. as first-line treatment or as a second step in case of recur-
rent/continued bacteremia despite appropriate antibiotic therapy.
• bacteremia with non-Pseudomonal/Serratia Gram-negative bacteria or 
Pneumococci in case of recurrent/continued bacteremia, in spite of appropri-
ate antibiotic therapy when no other identifiable source for recurrence or 
continued infection is found.
• patients with infective valve endocarditis without definite involvement of the 
CIED system.
The device must be completely removed as early as possible. Percutaneous 
removal is indicated as first choice when possible. Surgical approach is indicated 
when there is an indication for surgery associated with endocarditis in another 
location or after incomplete percutaneous removal. For large vegetations, greater 
than 20 mm, surgery may be considered the first option from the outset, due to 
a hypothetical higher risk of pulmonary embolism, although this cut-off point is 
arbitrary. The aspiration of large vegetations is reported before the percutaneous 
extraction of the electrodes. Removal of the system percutaneously is usually 
relatively simple when it is performed early after implantation, since there is 
less fibrosis around the device elements and implies more difficulty and risk of 
complications the longer the period after implantation and the complexity of 
the device.
The extraction should be done in expert centers by interventional cardiologists, 
electrophysiologists or cardiac surgeons. The percentage of complete removal of the 
device is high>90% with the techniques and materials currently available (specific 
stylets, mechanical dissection sheaths, with radiofrequency or laser, ties, etc.) 
(Figure 9). Implant removal requires centers with availability of urgent cardiac 
surgery, given that, although the percentage of complications is low, they can be 
serious and lead to vital compromise. The risk of serious complications is 2–4%, the 
most severe being cardiac avulsion or tear (CA / T) with tamponade and vascular 
avulsion or tear (VA/T). In the case of surgical extraction, (Figure 10) the percent-
age of complications observed is higher and it seems related to a greater severity of 
the patients [30–32].
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In 3–15% of patients with an indication of removal of the device, this will not be 
carried out for various reasons, especially a very high surgical risk or the patient’s 
own refusal [6, 10].
2.8.2 The antimicrobial therapy
Intravenous (iv) antimicrobial therapy should be guided whenever possible by 
microbiological documentation and antibiogram; this is the reason why the correct 
collection and sample processing is so important.
The empirical antibiotic regimens recommended by a consensus of various 
scientific societies, European Heart Rhythm Association (EHRA), Heart Rhythm 
Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin American Heart 
Rhythm Society (LAHRS), International Society for Cardiovascular Infectious 
Figure 10. 
Lead with big vegetation, surgical removal.
Figure 9. 
Materials for percutaneous.
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Diseases (ISCVID), European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID), European Association for Cardio-Thoracic Surgery (EACTS)] 
[30] are listed in Table 1. The duration of the treatment will continue once the 
device is removed as follows:
• Isolated pocket infection (negative blood culture): 10–14 days.
• Systemic infection without vegetation on leads or valves +/− pocket 
infection:
4 weeks (2 weeks if negative blood culture after extraction with total treatment 
duration not shorter than 4 weeks).
• Systemic infection: IE-CIED with vegetation on leads and/or valves + embo-
lism: 4–6 weeks + oral antibiotic therapy follow-up if indicated by secondary 
infectious focus.
Long-term suppressive therapy with iv antibiotic, according to the recommen-
dations in prosthetic valve endocarditis for 4–6 weeks, is reasonable for patients 
in whom the device cannot be totally or partially removed, due to the high rates of 
failure, relapse or reinfection [33].
2.9 New device implant
After the removal of a CIED, the indication for a new implant must be reconsid-
ered. This must be done critically and individually [19, 26, 30].
It is estimated that, in about 30% of patients, implantation of a new device is 
not indicated. The reason may be that there is no longer any indication, that the 
explanted device was not correctly indicated, or that the patient himself rejects 
a new implant. In the case of a new reimplantation, it will be necessary to assess 
whether a similar device is indicated, or whether it should be different, generally of 
less complexity or “downgrade” [31, 34].
If the indication for a new implant is confirmed, it should be deferred until 
the infection is controlled, if possible after obtaining negative blood cultures for 
at least 72 hours after the explant. In patients dependent on cardiac stimulation, 
who require temporary stimulation, an electrode ipsilateral to the explant will be 
used, through a venous access different from that used by the previous one. To 
prevent manipulations due to instability of the electrode, with a greater risk of 
contamination, the use of an active fixation electrode connected to an external 
battery and fixed to the skin is recommended, until it is safe to implant the defini-
tive device [6, 34].
If a device with electrodes (RTC, bicameral pacing) is indicated, it should be 
implanted initially on the contralateral side. If not, implantation of an epicar-
dial pacemaker or a MicraTM Transcatheter Pacing System (TPS; Medtronic, 
Minneapolis, MN, USA) femoral leadless pacemaker may be considered. The lead-
free pacemaker avoids the possibility of a primary infection of the generator pocket 
and thanks to its smaller overall surface area and the progressive encapsulation once 
implanted (Figure 11), it would theoretically present less risk of secondary infec-
tion in the presence of systemic infection [35].
In the case of patients with an indication for defibrillator reimplantation, 
without the need for permanent pacing, resynchronization or anti-tachycardia 
therapy, the implantation of a subcutaneous defibrillator should be considered 
(the infection rate requiring removal of the device is 2.4% after 3 years of follow 
up) (Figure 12) [36].
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Isolated pocket infection 10–14 days post-extraction
-Systemic symptoms
Empirical treatment/ - blood cultures -Vancomycin: 30–60 mg/kg/d iv in 2–3 doses
Directed at MR * CoNS and S Aureus -Alternative: Daptomycin 8–10 mg/kg iv od
+ Systemic symptoms +/−
(Empirical treatment/ - blood cultures) -Cephalosporin: standard dose
For additional Gram- coverage -Alternative: Gentamicin** 5–7 mg/kg iv od
After culture result Flucloxacillin: 8 g/d iv in 4 doses
If sensitive Staphylococcus Alternative: 1st generation cephalosporin 
standard dose
Partial oral treatment often used
Systemic infections without vegetation on leads or 
valves +/-pocket infection
4 weeks post-extraction_(consider 2w if 
-blood_cultures)
Empirical treatment/ - blood cultures Vancomycin: 30–60 mg/kg/d iv in 2–3 doses
Directed at MR Staphylococci and Gram- bacteria Alternative: Daptomycin 8–10 mg/kg od
+
Cephalosporin: standard dose iv
Alternative: Gentamicin 5–7 mg/kg iv o d
After culture result Flucloxacillin: 8 g/d iv in 4 doses
If sensitive Staphylococcus Alternative: 1st generation cephalosporin 
standard dose
Systemic infections with vegetation on leads or valves 
+/-pocket infection
Lead vegetation: 2 weeks post-extraction 
(total 4w except S Aureus)
Native valve vegetation: 4 weeks 
post-extraction
Prosthetic valve vegetation: (4-) 6 weeks 
post-extraction
Empirical treatment/ - blood cultures Vancomycin:30–60 mg/kg/d iv in 2–3 doses
Alternative: Daptomycin 8–10 mg/kg od
+
Cephalosporin: standard dose
Alternative: Gentamicin 5–7 mg/kg iv od
Adjust to culture result according to ESC endocarditis 
guidelines 2015
If prosthetic valve and staphylococcal infection: Add Rifampicin after 5–7 days: 900–1200  
mg/day orally (or iv) in 2 doses
*adapt to local resistance
**adjust according to kidney function od: once day
Table 1.
IE-CIED Empirical antibiotic regimens recommended.
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2.10 Prognosis
CIED infection is a serious pathology with a 30-day hospital mortality esti-
mated between 4.6–11% (despite the heterogeneity of the studies) [37]. Studies 
that included only patients with CIED -IE reported high mortality: 24.5–29% with 
follow-up periods of up to a year and explant rates of 80–100% [6]. It is associated 
with systemic infection and sepsis, complications derived from extraction and 
reimplantation and the own comorbidities of the patients. Long-term mortality is 
between 1.5 and 2.4 times higher than in CIED carriers without infectious complica-
tions. Mortality is high during the first year following CIED infection, but many 
deaths are not infection related. Abnormal renal function is the most consistently 
identified risk factor for mortality. Failure to remove an infected device is associated 
with relapse and mortality. CIED-IE has a higher mortality than localized generator 
pocket infection.
For all these reasons, infections in patients with CIED and especially those 
with suspected or confirmed systemic involvement should be considered a 
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made up of specialists in infectious diseases and microbiology, interventional 
cardiologists, electrophysiologists, clinicians and experts in multimodal imaging, 
surgeons and experts in other imaging techniques such as radiologists and nuclear 
medicine [38].
3. Conclusions
Infective endocarditis is a prevalent pathology in developed countries. Its 
spectrum is changing and its association with intracardiac devices has increased 
disproportionately in recent decades. Affected patients are especially vulnerable 
to complications due to both their cardiac and extra-cardiac pathologies and their 
frequent contact with health-related procedures. Most of these infections are caused 
by S Aureus and CoNS, many times carriers of antibiotic resistance and must be 
treated early and aggressively by multidisciplinary teams. We must be careful in the 
indication and choice of devices and exquisite in the prevention of infections since 
once established, therapeutic failure entails high morbidity and mortality.
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